CORDIS GUIDES ANALYSTS TO NEW RATINGS, STOCK INFLATES 15.8% TO 45
This article was originally published in The Gray Sheet
Executive SummaryCORDIS GUIDES ANALYSTS TO NEW RATINGS, STOCK INFLATES 15.8% TO 45 in July, as several analysts upgrade their ratings of the firm following a July 11 telephone conference in which Cordis President Bob Strauss reassured analysts about the recent downturn in the price of the company's stock. Cordis stock realized the bulk of its gain on the day of the conference, rising 3-3/4 to 40-1/4. The issue gained a total of 6-5/8 points for the month, making it the point leader on "The Gray Sheet" Index of NASDAQ-traded stocks for July.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.